33233781-A799-4610-86FC-C836713D31AA
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.490144546649145
- age_years
- 52
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.771
- INTERFERON_GAMMA_RESPONSE+0.651
- E2F_TARGETS+0.646
- G2M_CHECKPOINT+0.610
- IL6_JAK_STAT3_SIGNALING+0.462
- ALLOGRAFT_REJECTION+0.448
- MITOTIC_SPINDLE+0.441
- TGF_BETA_SIGNALING+0.429
- MYC_TARGETS_V2+0.413
- ANGIOGENESIS+0.391
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.404
- KRAS_SIGNALING_DN-0.396
- MYOGENESIS-0.274
- OXIDATIVE_PHOSPHORYLATION-0.233
- SPERMATOGENESIS-0.185
- BILE_ACID_METABOLISM-0.150
- ESTROGEN_RESPONSE_EARLY-0.144
- APICAL_SURFACE-0.112
- XENOBIOTIC_METABOLISM-0.094
- ESTROGEN_RESPONSE_LATE-0.062
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934846 | — | — | 0.943 |
| 2 | SRR934802 | — | — | 0.931 |
| 3 | SRR934949 | — | — | 0.930 |
| 4 | SRR934925 | — | — | 0.925 |
| 5 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.919 |
| 6 | SRR934753 | — | — | 0.918 |
| 7 | D717EAB5-3C67-4EF0-99BF-3416278BE492 | — | — | 0.918 |
| 8 | 15838786-D895-4F63-88A9-BDE627AE7958 | — | — | 0.917 |
| 9 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.916 |
| 10 | SRR934956 | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.771 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.651 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.646 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.610 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.462 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.448 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.441 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.429 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.413 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.391 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.378 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.368 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.358 | Inavolisib | — uncovered |
| APOPTOSIS | 0.337 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.336 | Inavolisib | — uncovered |
| COMPLEMENT | 0.333 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.319 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.313 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.297 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.275 | Inavolisib | — uncovered |